We are live on ! Find out more
CATX icon

Perspective Therapeutics
CATX

43 hedge funds and large institutions have $5.19M invested in Perspective Therapeutics in 2022 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 7 increasing their positions, 9 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 4

10% more funds holding

Funds holding: 39 → 43 (+4)

0.06% more ownership

Funds ownership: 1.12% → 1.18% (+0.06%)

10% less capital invested

Capital invested by funds: $5.79M → $5.19M (-$597K)

22% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 9

Holders
43
Holders Change
+4
Holders Change %
+10.26%
% of All Funds
0.72%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
7
Reduced
9
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VCM
Venator Capital Management
Ontario, Canada
+$168K
2
TMWM
Taylor & Morgan Wealth Management
Michigan
+$68.8K
3
PCM
Perkins Capital Management
Minnesota
+$35.4K
4
TSS
Two Sigma Securities
New York
+$9.69K
5
VF
Virtu Financial
New York
+$7.47K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$26.2K
2
Renaissance Technologies
Renaissance Technologies
New York
-$12.3K
3
BIM
Bullseye Investment Management
Ohio
-$9K
4
Northern Trust
Northern Trust
Illinois
-$5.25K
5
TRCT
Tower Research Capital (TRC)
New York
-$5K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$1.87M – – –
PCM
2
Perkins Capital Management
Minnesota
$901K +$35.4K +11,600 +4%
BlackRock
3
BlackRock
New York
$756K +$1.87K +613 +0.3%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$349K +$3.68K +1,204 +1%
TMWM
5
Taylor & Morgan Wealth Management
Michigan
$240K +$68.8K +22,535 +41%
BA
6
Bard Associates
Illinois
$207K – – –
State Street
7
State Street
Massachusetts
$171K – – –
VCM
8
Venator Capital Management
Ontario, Canada
$170K +$168K +55,000 New
Renaissance Technologies
9
Renaissance Technologies
New York
$117K -$12.3K -4,023 -10%
Northern Trust
10
Northern Trust
Illinois
$76K -$5.25K -1,719 -7%
BCM
11
Bridgeway Capital Management
Texas
$57K – – –
Creative Planning
12
Creative Planning
Kansas
$40K – – –
Morgan Stanley
13
Morgan Stanley
New York
$26K -$2.01K -657 -7%
Bank of New York Mellon
14
Bank of New York Mellon
New York
$24K – – –
Two Sigma Advisers
15
Two Sigma Advisers
New York
$17K -$3.48K -1,140 -17%
CAG
16
Crestwood Advisors Group
Massachusetts
$17K – – –
Citadel Advisors
17
Citadel Advisors
Florida
$13K -$26.2K -8,592 -68%
Millennium Management
18
Millennium Management
New York
$12K -$263 -86 -2%
Cerity Partners
19
Cerity Partners
New York
$12K – – –
Susquehanna International Group
20
Susquehanna International Group
Pennsylvania
$11K +$5.24K +1,714 +94%
WWA
21
WCG Wealth Advisors
Nevada
$11K +$10.4K +3,402 New
TSS
22
Two Sigma Securities
New York
$10K +$9.69K +3,173 New
BBNA
23
Bremer Bank National Association
Minnesota
$9K – – –
Royal Bank of Canada
24
Royal Bank of Canada
Ontario, Canada
$8K -$40 -13 -0.5%
Commonwealth Equity Services
25
Commonwealth Equity Services
Massachusetts
$8K – – –
1
2

CATX Hedge Fund Activity: Q2 2022 in Review

43 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Perspective Therapeutics (CATX) for Q2 2022, worth a combined $5.19M — down 10% from $5.79M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new CATX positions and 4 closed out — a net gain of 4 holders — while 7 added to existing stakes and 9 trimmed.

The largest buyer was Venator Capital Management, opening a new position worth an estimated $168K. The largest seller was Citadel Advisors, cutting an estimated $26.2K.

  • 43 institutional investors held Perspective Therapeutics (CATX) as of Q2 2022, up from 39 in Q1 2022.
  • Funds reported $5.19M of Perspective Therapeutics stock for Q2 2022, down 10% quarter-over-quarter.
  • 8 funds opened new Perspective Therapeutics positions in Q2 2022 and 4 closed out, a net change of +4 holders.
  • The largest Perspective Therapeutics buyer in Q2 2022 was Venator Capital Management, an estimated $168K added.
  • The largest Perspective Therapeutics seller in Q2 2022 was Citadel Advisors, an estimated $26.2K sold.

Based on aggregated 13F filings for Q2 2022.